Previous 10 | Next 10 |
home / stock / tevjf / tevjf news
The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2022 Q4 earnings call. For further details see: Teva Pharmaceutical Industries Limited 2022 Q4 - Results - Earnings Call Presentation
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
Summary Teva filed an ANDA challenge against Auvelity four months after approval. The filing defines, for me, the hurdles generics will face in challenging Axsome's huge patent estate. Expect more filings in the next 12-18 months, but these are not major hurdles for Axsome. ...
Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...
Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...
Summary Anda's revenue generated $450 million for the company in the last three months of 2022, up $95 million from Q4 2022, driven by substantially increased demand for the company's services. Teva's European segment profit was $1,496 million in 2022, slightly up year-over-year, even t...
Summary David Abrams’ 13F portfolio value decreased this quarter from $3.47B to $2.80B. The number of positions decreased from 18 to 15. The Meta Platforms stake was increased substantially while decreasing TransDigm Group, Energy Transfer, Alphabet, Willis Towers Watson, and Tev...
Teva Pharmaceutical Industries Limited (TEVA) Q4 2022 Earnings Conference Call February 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Head of Investor Relations Richard Francis - Chief Executive Officer Eli Kalif - Executive Vice President a...
Summary Catalyst's rights acquisition of FYCOMPA is a significant step towards controlling the epilepsy treatment market share. The company's cash balance of $256 million is enough to fund its CapEx in 2023. Teva's notice seeking to manufacture a generic version of FIRDAPSE poses a ...
Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Ltd Company Name:
TEVJF Stock Symbol:
OTCMKTS Market:
Teva Pharmaceutical Industries Ltd Website: